Surrozen, Inc./DE (SRZN) Form 8-K — Oct 20, 2026
Surrozen (Nasdaq: SRZN) closed the second and final tranche of its March 2025 private placement on October 20, 2026, generating approximately $95.1 million in gross proceeds before fees. The closing was triggered by FDA clearance of the IND for SZN-8141 on October 2, 2026. Investors received 5,741,605 shares at $11.60, pre-funded warrants for 2,456,500 shares, and Series E warrants for 4,099,052 shares at an $11.54 exercise price. Proceeds are expected to fund the company into 2029, covering the DUET Phase 1b/2a study of SZN-8141 (first patient dosing expected Q4 2026, initial data 2H 2027) and initial Phase 1b development of SZN-8143.
Key figures
- Cash Position
- 0
- Gross Proceeds
- 95100000
- Offering Price
- 11.6
- Shares Offered
- 5741605
- Shares Outstanding
- 17800000
- Cash runway
- into 2029
- Duet initial data
- second half of 2027
- Duet part2 patients
- approximately 60
- Series e warrant shares
- 4099052
- Prefunded warrant shares
- 2456500
- Duet first patient dosing
- Q4 2026
- Warrant shares outstanding
- 9100000
- Pre funded shares outstanding
- 3800000
- Series e warrant exercise price
- 11.54
- Prefunded warrant exercise price
- 0.0001
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.